Cargando…

Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations

Detalles Bibliográficos
Autores principales:	Mado, Hubert, Adamczyk-Sowa, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051542/ https://www.ncbi.nlm.nih.gov/pubmed/33864125 http://dx.doi.org/10.1007/s00415-021-10547-0

Ejemplares similares

Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab
por: Khayat-Khoei, Mahsa, et al.
Publicado: (2021)

Ocrelizumab: SARS-CoV-2 pneumonia: 2 case reports
Publicado: (2020)

SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy
por: Adamczyk-Sowa, Monika, et al.
Publicado: (2021)

Ocrelizumab/rituximab: SARS-CoV-2 infection: 2 case reports
Publicado: (2021)

Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report
por: Mado, Hubert, et al.
Publicado: (2021)

Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia
por: Conte, William L
Publicado: (2020)

Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
por: Gibson, Elena G, et al.
Publicado: (2021)

Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster
por: Landsberg, Hannah E., et al.
Publicado: (2022)

Skin testing with Pfizer SARS-CoV-2 vaccine and PEG 2000
por: Vieira, João, et al.
Publicado: (2021)

An explanation for SARS-CoV-2 rebound after Paxlovid treatment
por: Perelson, Alan S., et al.
Publicado: (2023)

Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab
por: Katz, J.D., et al.
Publicado: (2022)

Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab
por: Nytrova, Petra, et al.
Publicado: (2023)

Acute motor axonal neuropathy associated with the Pfizer SARS-CoV-2 vaccine
por: Nicolás-Sánchez, F.J., et al.
Publicado: (2022)

Transmission Cycle of SARS-CoV and SARS-CoV-2
por: Yadav, Tushar, et al.
Publicado: (2020)

Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV
por: Goyal, Rajat, et al.
Publicado: (2022)

Human Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 in Children
por: Aleebrahim-Dehkordi, Elahe, et al.
Publicado: (2021)

Data mining of coronavirus: SARS-CoV-2, SARS-CoV and MERS-CoV
por: Huh, Jung Eun, et al.
Publicado: (2021)

SARS-CoV, MERS-CoV and SARS-CoV-2: A Diagnostic Challenge
por: Ezhilan, Madeshwari, et al.
Publicado: (2021)

A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV
por: Zhou, Huan, et al.
Publicado: (2021)

What SARS-CoV-2 does to our brains
por: Aschman, Tom, et al.
Publicado: (2022)

Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
por: Lucchini, Matteo, et al.
Publicado: (2020)

Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022)

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
por: van Kempen, Zoé L. E., et al.
Publicado: (2022)

Persistent SARS-CoV-2 Infection in a Multiple Sclerosis Patient on Ocrelizumab: A Case Report
por: Ambadapoodi, Raghava S., et al.
Publicado: (2023)

SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development
por: de Souza Silva, Guilherme Antonio, et al.
Publicado: (2020)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
por: Abdelghany, T.M., et al.
Publicado: (2021)

Imaging findings in coronavirus infections: SARS-CoV, MERS-CoV, and SARS-CoV-2
por: Franquet, Tomas, et al.
Publicado: (2020)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals
por: Li, Meng, et al.
Publicado: (2023)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Petersen, Eskild, et al.
Publicado: (2020)

Correction to: Transmission Cycle of SARS-CoV and SARS-CoV-2
por: Yadav, Tushar, et al.
Publicado: (2020)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021)

Amyloidogenic proteins in the SARS-CoV and SARS-CoV-2 proteomes
por: Bhardwaj, Taniya, et al.
Publicado: (2023)

Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine
por: Zappa, Martina, et al.
Publicado: (2021)

A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson
por: Patel, Rikin, et al.
Publicado: (2022)

SARS-CoV-2
por: Steinbauer, M., et al.
Publicado: (2020)

Computational analysis of SARS-CoV-2, SARS-CoV, and MERS-CoV genome using MEGA
por: Sohpal, Vipan Kumar
Publicado: (2020)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
por: Zhang, Yun-yu, et al.
Publicado: (2020)

Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections
por: Fani, Mona, et al.
Publicado: (2020)

The emerging SARS-CoV, MERS-CoV, and SARS-CoV-2: An insight into the viruses zoonotic aspects
por: Al-Salihi, Karima A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k9d3s5hami2ovikj49us8bji3g